阿司匹林抵抗的产生机制与防治策略

被引:9
作者
张仁岗
张军平
机构
[1] 天津中医药大学第一附属医院心内科
关键词
阿司匹林; 疾病特征; 心血管疾病; 抗血栓形成药;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
阿司匹林属于非甾体类抗炎药,尽管被广泛应用于临床已有百余年,但有关其作用机制及临床应用的研究一直在进行。阿司匹林由最初的被用于解热、镇痛、抗炎等逐渐转变到用于抗血栓,尤其在心血管事件的二级预防中应用最广,减少了大约25%的心血管事件的发生。临床上有5%60%的患者虽常规服用阿司匹林,却不能有效地抑制血小板的活性,这种现象被称为阿司匹林抵抗。导致这种现象的确切原因还不明确,可能与药物间的相互作用、剂量不足等有关。但到目前为止,仍无法用同一机制解释所有的阿司匹林抵抗,并且,很多研究所得出的结果是矛盾的。因此,认为在具有阿司匹林抵抗的人群中可能存在一定的群体特征性,也正因如此导致了阿司匹林抵抗的复杂性。期望用同一机制解释所有的阿司匹林抵抗现象是不可行的,应当针对不同群体做更多的研究工作。按照传统中医理论,结合心血管疾病多病程较长,且在存在阿司匹林抵抗的人群中多反复发作等特点,应将其归属于络病的范畴。联合应用具有扶正化浊,活血解毒通络功效的中药,发挥中医中药辨证论治和整体调节的优势,也许可以解决具有不同群体特征性的阿司匹林抵抗的问题,从而更有效地预防心血管疾病的发生。
引用
收藏
页码:259 / 262
页数:4
相关论文
共 19 条
[1]  
Flowcytometry analysis of platelet cyclooxygenase-2 expression:induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Weber AA,Przytulski B,Schumacher M,et al. British Journal of Haematology . 2002
[2]  
Aspi-rin response and failure in cerebral infarction. Helgason CM,Tortorice KL,Winkler SR,et al. Stroke . 1993
[3]  
Resistancein vitroto low-dose aspirin is associated with plateletPlA1(GP IIIa)polymorphism but not with C807T(GPIa/IIa)and C-5T Kozak(GP Ibalpha)polymorphisms. Macchi L,Christiaens L,Brabant S,et al. Journal of the American College of Cardiology . 2003
[4]  
Platelet inhibi-tion by aspirin is diminished in patients during carotidsurgery:a form of transient aspirin resistance. Payne DA,Jones CI,Hayes PD,et al. Thrombosis and Haemostasis . 2004
[5]  
Resistanceto aspirinin vitrois associated with increased plateletsensitivity to adenosine diphosphate. Macchi L,Christiaens L,Brabant S,et al. Thrombosis Research . 2002
[6]  
Profile and prevalence of aspirin resistance in patientswith cardiovascular disease. Gum PA,Kottke-Marchant K,Poggio ED,et al. The American Journal of Cardiology . 2001
[7]  
Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Rocca B,Secchiero P,Ciabattoni G,et al. Proceedings of the National Academy of Sciences of the United States of America . 2002
[8]  
Patientsexposed to rofecoxib and celecoxib have different odds ofnonfatal myocardial infarction. Kimmel SE,Berlin JA,Reilly M,et al. Annals of Internal Medicine . 2005
[9]  
Collaborativemeta-analysis of randomised trials of antiplatelet therapyfor prevention of death,myocardial infarction,andstroke in high risk patients. Antithrombotic Trialists’Collaboration. British Medical Journal . 2002
[10]  
Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Nurtjahja-Tjendraputra E,Ammit AJ,Roufogalis BD,et al. Thrombosis Research . 2003